Biosimilars in the Treatment of Retinal Disease in the United States

Biosimilars have recently emerged into the vitreoretinal pharmaceutical market. This re-view defines biosimilars, discusses the approval process, and reviews the benefits, risks, and contro-versies regarding biosimilars. This review also dis-cusses ranibizumab biosimilars that have recently received United States Food and Drug Administra-tion approval in the United States and discusses anti-vascular endothelial growth factor biosimilars that are in development.